SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dorightbythem who wrote (63259)9/30/2025 1:29:42 AM
From: li35111 Recommendation

Recommended By
bodish

  Read Replies (1) of 63276
 
Other than name-checking a specific commercial product, and insinuating without evidence that it was actually ineffective, the gist of his comments were spot on. All approvals based on surrogate endpoints should have follow-up studies to prove actual clinical benefit. That’s not too much to ask for. That voclosporin has “significant toxicities” is hardly news. en.wikipedia.org

Meanwhile, thanks for the opportunity to sell AUPH October puts this afternoon!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News